Alnylam intends to appeal ruling on two patents asserted against Moderna

Alnylam (ALNY) announced an update on its ongoing patent infringement litigation. On March 17, 2022, Alnylam initiated litigation in the United States District Court for the District of Delaware against Moderna (MRNA) for patent infringement. To date, in two separate actions against Moderna, Alnylam has sought to recover reasonable compensation for Moderna’s infringement of five Alnylam patents that cover key lipid technology embedded in Moderna’s COVID-19 Vaccine, Spikevax. On August 21, the Delaware Court issued an order construing certain claim terms in two of the asserted Alnylam patents. In light of that order, Alnylam and Moderna have jointly agreed to final judgment of non-infringement of two of Alnylam’s patents. Alnylam respectfully disagrees with the Delaware Court’s ruling and intends to appeal the decision. Alnylam anticipates that its second action against Moderna for infringement will move forward in the Delaware Court. The Delaware Court’s claim construction ruling did not impact Alnylam’s infringement contentions in its two separate suits against Pfizer (PFE). Alnylam will continue to assert six patents against Pfizer to recover reasonable compensation for Pfizer’s use of Alnylam’s technology in its COVID-19 vaccine, Comirnaty.